Filing Details
- Accession Number:
- 0001209191-21-061975
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-28 19:54:42
- Reporting Period:
- 2021-10-26
- Accepted Time:
- 2021-10-28 19:54:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1370053 | Anaptysbio Inc | ANAB | Pharmaceutical Preparations (2834) | 203828755 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1654495 | Hamza Suria | C/O Anaptysbio, Inc. 10770 Wateridge Circle, Suite 210 San Diego CA 92121 | President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-10-26 | 15,993 | $1.12 | 83,629 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-10-26 | 15,993 | $30.00 | 67,636 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-10-26 | 15,993 | $0.00 | 15,993 | $1.12 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
73,291 | 2022-01-31 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022.
- In addition to the remaining options to purchase 73,291 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.